Drug Trial Radar · NCT06061536
Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.
Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Nov 2, 2023
Primary completion
Nov 29, 2024
Study completion Jan 24, 2025
Sponsor
- Lead sponsor
- Shanxi Kangbao Biological Product Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Institute of Pathogen Biology, Beijing, China
- First posted
- Sep 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, controlled, open-label, dose-exploration study to assess the effectiveness and safety of Lipovirtide combined with nucleoside drugs in HIV-infected patients who have not received antiviral treatment before.
Conditions
- HIV
Interventions
Lipovirtide 10mgDrug
Lipovirtide 10mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily);
Lipovirtide 40mgDrug
Lipovirtide 40mg+3TC+TDF(LP-80:once a week;3TC+TDF:once daily);
Lipovirtide 60mgDrug
Lipovirtide 60mg+3TC+TDF(LP-80:once every 2 weeks;3TC+TDF:once daily);
DTGDrug
DTG +3TC + TDF(once daily).
Primary outcomes
What the sponsor says the trial is designed to measure.
- HIV-1 RNA <50 copies/mlTime frame: at Day 169 after receiving Lipovirtide administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Second People's Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.